Stable Parkinson’s Disease Drug Therapy Status Quo Could Soon Be Disrupted by New Category Entrants
Burlington, Massachusetts-based, medical market research firm Decision Resources Group (DRG) reports, citing analyses of U.S. longitudinal patient-level claims data, that the Parkinson’s disease (PD) drug treatment algorithm remains highly stable, with levodopa (either alone or in combination with carbidopa) as its foundation. Parkinson’s disease (PD) is a…